The Saudi Food and Drug Authority (SFDA) has finalized its comprehensive, integrated operational plan for the Hajj season 1447 AH (2026). This readiness aligns with the directives of the Kingdom of Saudi Arabia’s wise leadership to prioritize the health and well-being of pilgrims, leveraging all available resources to ensure a safe and seamless Hajj journey. These efforts underscore the Kingdom’s longstanding commitment to the service and care of the Two Holy Mosques and their visitors.

The Saudi Food and Drug Authority (SFDA) has granted Eli Lilly Breakthrough designation to Bemlayo (Orforglipron), which is indicated as an adjunct to healthy diet and physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.

The Saudi Food and Drug Authority (SFDA) has granted Santhera Pharmaceuticals orphan drug designation to Agamree (vamorolone), which is indicated for the treatment of patients with Duchenne muscular dystrophy (DMD).

Registration is Subject to Full Scientific Evaluation